However, in Japanese clinical practice, most patients with NSCLC undergo testing for oncogenic mutations and programmed cell death ligand 1 expression before treatment, and treatment decisions are made according to established guidelines [29, 56]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.